Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ReN 003

Next Previous
X
Search
Drug Profile

ReN 003

Alternative Names: hRPC therapy - ReNeuron; hRPC-ReNeuron; ReN003; Retinal stem cell therapy-ReNeuron

Latest Information Update: 24 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard Medical School; ReNeuron; Schepens Eye Research Institute
  • Developer ReNeuron
  • Class Eye disorder therapies; Neural stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Retinitis pigmentosa

Most Recent Events

  • 18 Jan 2022 ReN 003 is available for licensing as of 18 Jan 2022. https://www.reneuron.com/contact/contact-us/
  • 18 Jan 2022 Phase-II clinical trials in Retinitis pigmentosa in Spain, USA, United Kingdom (Subconjunctival) as of January 2022
  • 01 Oct 2021 ReNeuron plans a phase III trial for Retinitis pigmentosa by the end of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top